IFNGR1 and neoplasm: To further examine the impact of IFN-γ signaling in tumor cells, we used CRISPR-Cas9 to knockout the interferon gamma receptor 1 (IFNGR1) in B7-H3 knockdown 105K cells (Fig. 6n).